Goldman L I
Semin Oncol. 1975 Jun;2(2):175-8.
Survival from malignant melanoma has been serially followed over a long period of time. A summation of this information is seen in Table 5. The steadily improving 5- and 10-yr disease-free intervals in stage I disease probably represents a combination of increased awareness of early lesions and the application of aggressive, initial surgical treatment. The ominous and essentially unchanged prognosis in stage II disease reinforces this goal. Suspicion and gross recognition of early melanoma is essential. Adequate biopsy with the appropriate classification provides the surgeon with insight into the correct therapy. This usually entails wide, three-dimensional excision and wound closure by free skin-grafting. Regional lymphadenectomy is performed whenever anatomical and microscopic conditions dictate the need. The roles of amputation, regional perfusion, and adjuvant therapy require clarification. Studies are being pursued to provide firm data concerning the value of these methods.
恶性黑色素瘤患者的生存率已被长期连续跟踪。表5总结了这些信息。I期疾病中5年和10年无病间期的稳步改善可能是早期病变意识提高以及积极的初始手术治疗应用的综合结果。II期疾病预后不佳且基本未变强化了这一目标。对早期黑色素瘤的怀疑和肉眼识别至关重要。进行充分的活检并进行适当分类，可为外科医生提供正确治疗的依据。这通常需要进行广泛的三维切除，并通过游离植皮进行伤口闭合。只要解剖学和显微镜检查情况表明有必要，就进行区域淋巴结清扫术。截肢、区域灌注和辅助治疗的作用需要阐明。正在进行相关研究以提供有关这些方法价值的确切数据。
